At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Single-arm, Open-label, Non-randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-booster Dosing Schedule Among 9-11 Year-old Girls and Boys
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Recombinant Human Papillomavirus Nonavalent Vaccine for Human Papillomavirus-Related Carcinoma. Active but no longer recruiting, targeting 201 participants across 2 sites.
Detailed Summary
Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx over many years among adults. This phase IIA trial studies how well does the nonavalent HPV vaccine (which can prevent nine different types of HPV) work when given in an alternative dosing schedule to heathy young research participants.
Study Details
Timeline
Interventions
Correlative studies
Given IM